A Study to Evaluate the Effect of KarXT on Urological Safety
← catalyst calendarNCT07221877 · readout in 498 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 4
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
60estimated
Sites
13
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-20 | actual | When the study began enrolling |
| Primary completion | 2027-12-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Schizophrenia
Intervention
- Drug: Xanomeline/trospium chloride — also filed as KarXT, BMS-986510
Primary outcomes
what the primary-completion date above is the date OFChange from baseline in voiding dynamics (Qmax) over time
measured Up to 12 months
Change from baseline in post-void residual volume (PVR) over time
measured Up to 12 months
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed